Double-Blind Randomized Efficacy Field Trial of Alum Precipitated Autoclaved Leishmania major (Alum-ALM) Vaccine Mixed With BCG Plus Imiquimod Vs. Placebo Control Group
-
Mohammad BARATI
,
Mehdi MOHEBALI
,
Mohammad Hossein ALIMOHAM¬MADIAN
,
Ali KHMESIPOUR
,
Hossein KESHAVARZ
,
Behnaz AKHOUNDI
,
Zabi¬hollah ZAREI
Abstract
Background: Canine visceral leishmaniasis (CVL) is not only an emerging veterinary concern but also a public health threat in endemic areas. The aim of this study was to assess the efficacy, immunogenicity and safety of two doses of aluminum hydroxide (alum) precipitated Leishmania major (Alum-ALM) mixed with BCG plus imiquimod against CVL.
Methods: A total of 560 ownership dogs were serologically tested and 234 healthy dogs with no clinical signs of CVL, no anti-Leishmania antibodies and negative leishmanin skin test were selected and double-blind randomly injected intradermally either with 0.1 ml Alum-ALM (200µg protein) mixed with BCG (2 × 106 CFUs) plus imiquimod (121 dogs) or with 0.1 ml of normal saline (113 dogs).
Results: The follow-up examinations showed that there was no side effect associated with the vaccination except one case. Strong skin test conversion were seen in vaccinated group (30.3%) compared to the control group (6.6%) at 22-24 weeks after the booster injection (p<0.001). The seroconversion was 16.3% (18/110) in vaccinated group and 26.4% (28/106) in control group after two transmission cycles but the difference was not significant (P=0.095). The efficacy rate based on seroconversion was 40.4 %.
Conclusion: Two injections of Alum-ALM mixed with BCG and imiquimod is safe, although decreases the seroconversion rate of CVL, but the overall efficacy was low.
Alvar J, Molina R, San Andres M, Tesouro M, Nieto J, Vitutia M, et al. Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol. 1994;88(4):371-8.
Desjeux P. Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis. 2004;27(5):305-18.
Baneth G, Koutinas AF, Solano-Gallego L, Bourdeau P, Ferrer L. Canine leishmaniosis - new concepts and insights on an expanding zoonosis: part one. Trends Parasitol. 2008; 24(7):324-30.
Gavgani AS, Mohite H, Edrissian GH, Mohebali M, Davies CR. Domestic dog ownership in Iran is a risk factor for human infection with Leishmania infantum. Am J Trop Med Hyg. 2002;67(5):511-5.
Mohebali M. Visceral leishmaniasis in Iran: Review of the Epidemiological and Clinical Features. Iran J Parasitol. 2013;8(3):348-58.
Mohebali M, Hajjaran H, Hamzavi Y, Mobedi I, Arshi S, Zarei Z, et al. Epidemiological aspects of canine visceral leishmaniosis in the Islamic Republic of Iran. Vet Parasitol.2005; 129(3-4):243-51.
Moshfe A, Mohebali M, Edrissian G, Zarei Z, Akhoundi B, Kazemi B, et al. Seroepidemiological Study on Canine Visceral Leishmaniasis in Meshkin-Shahr District, Ardabil Province, Northwest of Iran during 2006-2007. Iran J Parasitol. 2008;3(3):1-10.
Barati M, Mohebali M, Alimohammadian M, Khamesipour A, Akhoundi B, Zarei Z. Canine
visceral leishmaniasis: seroprevalence survey of asymptomatic dogs in an endemic area of northwestern Iran. J Parasitic Dis.2015; 39(2):221–224.
Hadighi R, Boucher P, Khamesipour A, Meamar AR, Roy G, Ouellette M, et al. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis are sensitive to alternative antileishmania drugs. Parasitol Res. 2007;101(5):1319-22.
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006 ;19(1):111-26.
Khamesipour A. Therapeutic vaccines for leishmaniasis. Expert Opin Biol Ther. 2014 ;14(11):1641-9.
Gradoni L, Gramiccia M, Mancianti F, Pieri S. Studies on canine leishmaniasis control. 2. Effectiveness of control measures against canine leishmaniasis in the Isle of Elba, Italy. Trans R Soc Trop Med Hyg. 1988;82(4):568-71.
Dietze R, Barros GB, Teixeira L, Harris J, Michelson K, Falqueto A, et al. Effect of eliminating seropositive canines on the transmission of visceral leishmaniasis in Brazil. Clin Infect Dis. 1997 ;25(5):1240-2.
Palatnik-de-Sousa CB, dos Santos WR, Franca-Silva JC, da Costa RT, Reis AB, Palatnik M, et al. Impact of canine control on the epidemiology of canine and human visceral leishmaniasis in Brazil. Am J Trop Med Hyg. 2001;65(5):510-7.
Ashford DA, David JR, Freire M, David R, Sherlock I, Eulalio MC, et al. Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg. 1998;59(1):53-7.
Mohebali M, Edrissian GH, Shirzadi MR, Hosseingholizadeh G, Pashaei MH, Ganji A, et al. Integrated visceral leishmaniasis surveillance system in primary care for children in Meshkin-Shahr district, north-western Islamic Republic of Iran. East Mediterr Health J. 2010 ;16(10):1050-4.
Alvar J, Croft SL, Kaye P, Khamesipour A, Sundar S, Reed SG. Case study for a vaccine against leishmaniasis. Vaccine. 2013;31 Suppl 2:B244-9.
Gradoni L. An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol. 2001;100(1-2):87-103.
Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamesipour A, Ehsasi S, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol. 1996;14(5):489-95.
Mohebali M, Javadian E, Hashemi-Fesharki R, Mohammadzadeh M, Nadim A. Trial of non-living crude vaccine against zoonotic cutaneous leishmaniasis. Med J Islamic Republic Iran 1995;8(4):211–15.
Mohebali M, Fallah E, Jamshidi S, Hajjaran H. Vaccine trial against canine visceral leishmaniasis in the Islamic Republic of Iran. East Mediterr Health J. 1998;4 (2):234–8.
Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine. 2008 ;26(52):6759-67.
Noazin S, Khamesipour A, Moulton LH, Tanner M, Nasseri K, Modabber F, et al. Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis. Vaccine. 2009 ;27(35):4747-53.
Badiee A, Heravi Shargh V, Khamesipour A, Jaafari MR. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends. Vaccine. 2013;31(5):735-49.
Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG. Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol. 2012;3:144.
Johnston D, Bystryn JC. Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine. Vaccine. 2006;24(11):1958-65.
Zhang WW, Matlashewski G. Immunization with a Toll-like receptor 7 and/or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun. 2008;76(8):3777-83.
Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis. 2001;33(11):1847-51.
Miranda-Verastegui C, Llanos-Cuentas A, Arevalo I, Ward BJ, Matlashewski G. Randomized, double-blind clinical trial of topical imiquimod 5% with parenteral meglumine antimoniate in the treatment of cutaneous
leishmaniasis in Peru. Clin Infect Dis. 2005 ;40(10):1395-403.
Miranda-Verastegui C, Tulliano G, Gyorkos TW, Calderon W, Rahme E, Ward B, et al. First-line therapy for human cutaneous leishmaniasis in Peru using the TLR7 agonist imiquimod in combination with pentavalent antimony. PLoS Negl Trop Dis. 2009;3(7):e491.
Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. Arch Dermatol. 2006;142(12):1575-9.
Rassi Y, Javadian E, Nadim A, Rafizadeh S, Zahraii A, Azizi K, et al. Phlebotomus perfiliewi transcaucasicus, a vector of Leishmania infantum in northwestern Iran. J Med Entomol. 2009 ;46(5):1094-8.
Oshaghi MA, Ravasan NM, Hide M, Javadian EA, Rassi Y, Sadraei J, et al. Phlebotomus perfiliewi transcaucasicus is circulating both Leishmania donovani and L. infantum in northwest Iran. Exp Parasitol. 2009 ;123(3):218-25.
el Harith A, Slappendel RJ, Reiter I, van Knapen F, de Korte P, Huigen E, et al. Application of a direct agglutination test for detection of specific anti-Leishmania antibodies in the canine reservoir. J Clin Microbiol. 1989 ;27(10):2252-7.
Mohebali M, Edrissian GH, Nadim A, Hajjaran H, Akhoundi B, Hooshmand B, et al. Application of Direct Agglutination Test (DAT) for the Diagnosis and Seroepidemiological Studies of Visceral Leishmaniasis in Iran. Iran J Parasitol. 2006;1(1):15-25.
Alimohammadian M, Hakimi H, Nikseresht M. The preparation and evaluation of reference leishmanin from Leishmania major for use in man for diagnostic and experimental purposes. Med J Islamic Republic Iran 1993;7:23–8.
Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J Med Res. 2006 Mar;123(3):423-38.
Palatnik-de-Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine. 2008 ;26(14):1709-24.
Palatnik-de-Sousa CB. Vaccines for canine leishmaniasis. Front Immunol. 2012;3:69.
| Files | ||
| Issue | Vol 10 No 3 (2015) | |
| Section | Original Article(s) | |
| Keywords | ||
| Alum Leishmania major Vaccine Canine visceral leish-maniasis BCG Imiquimod Iran | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
